Sanofi secures rights to Ascenta's experimental cancer drugs

06/6/2010 | Reuters

Biotech firm Ascenta Therapeutics agreed to license its cancer drug candidates, including MI-773 and MI-519-64, to Sanofi-Aventis. The deal entitles Ascenta to get as much as $398 million from Sanofi.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Assistant General Counsel, Regulatory
Cardinal Health
Waukegan, IL
Chief Executive Officer
UCare Minnesota
Minneapolis, MN